October - 2020

MECFA Blog

Preclinical Work Supports ELX-02, Potential Treatment for Nonsense Mutations

Eloxx Pharmaceuticals presented preclinical safety and efficacy data supporting ELX-02, its investigational treatment for cystic fibrosis...

Cystic fibrosis (CF) and staphylococcus aureus infections

Staphylococcus aureus (known as staph) is a bacterium that is quite common in the general population. If someone with cystic fibrosis...

New medical trial for Cystic Fibrosis patients helps with medication side effects

The coronavirus pandemic has had a surprising benefit for cystic fibrosis patients. Dr. Perry Brown, with the St. Luke's Idaho Cystic...

IV antibiotics not superior to oral therapy for eradicating P. aeruginosa in cystic fibrosis

Treatment with IV antibiotics, compared with oral therapy, did not achieve sustained eradication of Pseudomonas aeruginosa in a greater...

Treating cystic fibrosis with mRNA therapy or CRISPR

New Rochelle, NY, October 8, 2020--The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is...

Certain Factors Could Predict Severe Episodes of Coughing Up Blood in CF Patients, Study Says

Factors such as diabetes, a specific type of fungal infection, and previous mild to moderate episodes of hemoptysis, or coughing up...

Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the NACFC

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology...

Lenabasum Fails to Lessen Exacerbations in CF Patients in Phase 2 Trial

A Phase 2 clinical trial of oral lenabasum in people with cystic fibrosis (CF) failed to meet its primary goal of reducing pulmonary...

FDA Grants Approval To Ivacaftor For Treatment Of Cystic Fibrosis In Infants

Study did not meet primary endpoint of reducing rate of pulmonary exacerbations Lenabasum treatment had a favorable safety profile and...

Oral antibiotics are as effective as IV antibiotics for the eradication of PseudomonasOral antibiot

The results of the long-running 'Torpedo' clinical trial investigating two different approaches to the eradication of a serious cystic...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p